The LMP-1 oncoprotein of EBV is required to maintain proliferation of infected B-cells and shares several features with CD40, TNF-R1, and related receptors. Members of this family can bind TRAF and TRADD molecules and activate NF-kB and AP-1, as can LMP-1. While CD40 and TNF-R1 are dependent on binding their ligands for their signaling, LMP-1 apparently is not. We have found that LMP-1 can act as a governor of cell proliferation and thereby limit its own activities. Its inhibition of proliferation is not mediated by apoptosis but results in cytostasis in four cell lines tested. The structural moiety of LMP-1 that distinguishes it from CD40 and TNF-R1, its amino-terminus and multiple membrane spanning segments, alone can mediate its cytostatic activity.
Introduction
In an apparent paradox, multiple oncogenes have both growth-promoting and growth-inhibitory eects on cells. The cellular oncogenes Ras, c-Myc and Bcl-2, and the viral oncogenes E1A and E7 all contribute to cell proliferation or survival. However, under certain conditions these oncogenes suppress cell proliferation either by growth arrest or by induction of P53-dependent and -independent apoptosis (Debbas and White, 1993; Evan and Littlewood, 1998; Evan et al., 1992; Howes et al., 1994; O'Reilly et al., 1996; Serrano et al., 1997; Shi et al., 1992) . These oncogenes apparently have mechanisms to suppress their oncogenic potential (Evan and Littlewood, 1998) . In addition to these oncogenes, Epstein-Barr virus' (EBV) latent membrane protein one (LMP-1) has this paradoxical role in both inducing and inhibiting cell proliferation. We have characterized LMP-1's ability to inhibit cell proliferation.
LMP-1 behaves as a ligand-independent, constitutively active receptor . It shares multiple features with CD40 and TNF-R1. All three proteins activate NF-kB (Berberich et al., 1994; Mitchell and Sugden, 1995; Rothe et al., 1994) ; LMP-1 and TNF-R1 bind TRADD (Hsu et al., 1995; Izumi and Kie, 1997) ; LMP-1, TNF-R1, and CD40 bind TRAF molecules (Brodeur et al., 1997; Devergne et al., 1996; Hu et al., 1994; Mosialos et al., 1995; Rothe et al., 1994; Sandberg et al., 1997) and can activate AP-1 (Kieser et al., 1997) ; and the carboxy terminus of CD40 can substitute for that of LMP-1 under some conditions . Both LMP-1 and CD40 can aect proliferation of the cell, but while those eects of CD40 are regulated by access to its ligand, LMP-1 apparently has no ligand (Martin and Sugden, 1991a) . The structure of LMP-1 diers strikingly from that of CD40 and other related receptors: LMP-1 has six membrane-spanning segments while CD40 and its relatives have only one. We have found that the amino-terminus and multiple membrane-spanning segments of LMP-1 have an activity not formerly associated with them; they limit proliferation of the host cell. LMP-1 has evolved a novel means to limit its positive aects on cell growth.
When LMP-1 is expressed eciently in a variety of cells it inhibits their proliferation (Cuomo et al., 1992; Floettmann et al., 1996; Hammerschmidt et al., 1989) . We have found that this inhibition is not a result of apoptosis. For example, inhibitors of apoptosis do not aect this inhibition nor is p53 required for it. Singlecell assays indicate that ecient expression of LMP-1 upon transfection renders a recipient cell cytostatic but does not cause its lysis. Conditional expression of LMP-1 uniformly in a population renders the cells cytostatic, inhibiting their progress through the cell cycle at all stages. These cells remain cytostatic but intact for at least 7 days and can be induced to proliferate if the expression of LMP-1 is decreased. Importantly, levels of expression in these clones is only 1 ± 4-fold that found in EBV-positive lymphoblastoid cell lines indicating that LMP-1's acting as a governor of cell proliferation is likely to occur under physiological conditions.
A panel of derivatives of LMP-1 were examined to map those regions required for its induction of cytostasis. Neither the TRAF-binding domain nor its NF-kB or AP-1 activation domains are essential for it to induce cytostasis. Mutants that alter the localization or structure of its six membrane-spanning regions without aecting its presence in the plasma membrane diminish or abrogate its induction of cytostasis. Strikingly, a derivative that deletes all of its carboxy terminus (that portion of LMP-1 involved most directly in signaling) is fully capable of inhibiting cell proliferation. These analyses demonstrate that LMP-1 can self-regulate its positive eects on proliferation through its amino-terminus and multiple membrane segments.
That LMP-1 can act as an inhibitor of cell proliferation has unexpected implications. LMP-1's inhibition may contribute to the control of the number of viral genomes in cells immortalized by EBV and its absence may be involved in EBV's tumorigenicity. Burkitt's lymphomas evolve to express only EBNA-1 among EBV's oncogenes (Rowe et al., 1987) . The lack of expression of LMP-1 and other viral proteins has been interpreted to provide these tumor cells an advantage by escaping immune responses directed against viral proteins. Another advantage may be loss of the limitation LMP-1 can impose on proliferation of EBV-positive cells.
Results

LMP-1's ability to inhibit cell proliferation results from cytostasis rather than cytotoxicity
Ecient expression of LMP-1 in cells (as little as twofold higher expression than in the EBV-positive LCL 721 [ Figure 3c and data not shown]), leads to a loss of their progeny. This loss of progeny has been measured in acute and long-term assays by counting progeny cells (Hammerschmidt et al., 1989) . We have asked if this loss of progeny results from induction of apoptosis and could consequently be inhibited with known inhibitors of apoptotic pathways. In particular we have measured LMP-1's possible cytotoxic eects in p53-null cells, in the presence of the caspase inhibitors, CrmA and P35, and in the presence of eciently expressed Bcl-2.
The loss of progeny cells mediated by ecient expression of LMP-1 was assayed by introducing expression vectors for LMP-1 and its derivatives ( Figure 1 ) along with one for b-galactosidase. Additional vectors expressing CrmA, P35, and Bcl-2 were introduced into recipient cells which either did or did not express p53. The ecient expression of wild type LMP-1 reduced the number of b-gal-positive cells 72 h after transfection. The loss of progeny occurred in p53-positive and -negative cells (Table 1) , in the presence of CrmA, P35, and Bcl-2 (Table 2) . Cells were lost when treated with aFAS antibody; however, this loss was inhibited when the cells were transfected with vectors for CrmA, P35, and Bcl-2 prior to treatment (Table 3) . Because in these studies with LMP-1 there is no statistically signi®cant dierence (P40.05) between cells transfected with vectors expressing the inhibitors Figure 1 The structure of wild-type LMP-1 and its derivatives. Wild-type LMP-1 depicted on the left is derived from a genomic clone of LMP-1 (EBV nucleotides 169,476 to 167,920), is driven by the immediate early CMV promoter/enhancer of pCMV (vector) (Hammerschmidt, et al., 1989) , and encodes a 386 amino acid protein with the transmembrane domains (shown as open boxes) as marked. The derivatives ND25 and CD55 are depicted on the left and right, have the deletions marked, and have previously been described (Hammerschmidt, et al., 1989; Martin and Sugden, 1991b) . The 6MHALMP-1 derivative is depicted on the left and has a HA epitope (shown by black dot) between amino acids 2 and 3 of wild-type LMP-1. 4MHALMP-1 depicted on the left, is a derivative of 6MHALMP-1, with a deletion in the sequence from 24 to 64 as marked. EELMP-1 depicted on the right is a derivative of wild-type LMP-1 with an EE epitope (shown by checkered box) substituted for amino acids 12 to 20. Sub 2 and Sub 4 depicted on the right are derivatives of wild-type LMP-1 and have the histidines and charged amino acids changed to alanines between amino acids 205 to 215 and 221 to 231 respectively as marked (shown as dotted boxes) (Sandberg, et al., 1997) . LMP/EGFP and ND25/ EGFP depicted on the left are derivatives of wild-type LMP-1 which have EGFP (larger checkered rectangle) fused at amino acid 323 (the unique MfeI site in the LMP-1 coding sequence) as indicated. The 6MHALMP-1EE depicted on the right, is a derivative of 6MHALMP-1, and has 2 EE-epitopes in place of the entire carboxy-terminus of LMP-1 LMP-1 inhibit cell proliferation A Kaykas and B Sugden of apoptosis and cells not receiving those vectors, we conclude that the loss of cell progeny mediated by ecient expression of LMP-1 can not be prevented by these inhibitors.
These ®ndings indicate that ecient expression of LMP-1 is unlikely to induce apoptosis. LMP-1's ability to inhibit cell proliferation could generally result from cytostasis rather than cytotoxicity (Floettmann et al., 1996) . To test this possibility, LMP-1 was fused to enhanced green¯uorescent protein (EGFP) so that LMP-1-positive cells could be readily identi®ed. These fusion proteins behave as do their unfused LMP-1 counterparts, in that they inhibit the formation of progeny cells to a similar extent as measured by a diminution of cells that express b-gal (Table 4) . Expression vectors for LMP/EGFP fusions were introduced into Hep2 cells and 72 h later both the number of colonies and the number of EGFP-positive cells per colony were counted. We used Hep2 cells as LMP-1 has previously been shown to inhibit their proliferation in acute assays (Hammerschmidt et al., 1989) . Transfected cells that express the LMP/EGFP fusion protein failed to give rise to colonies of more than two positive cells, whereas cells not expressing the fusion protein gave rise to colonies of more than 11 cells by 72 h (Table 5 ). In contrast, EGFP alone or a fusion with the ND25 derivative (Figure 1) , which is greatly reduced in its ability to inhibit proliferation relative to wild-type LMP-1, yielded colonies with an average of seven and ®ve positive cells, respectively. This result indicates that LMP-1-expressing cells fail to proliferate not because they lyse but rather because they are rendered cytostatic. An alternative explanation we ®nd unlikely is that LMP-1-expressing cells are dying and proliferating at the same rate. For tissue homeostasis, such as in the small intestine, in which cell death and proliferation occur at similar rates, death is mediated by apoptosis (Potten et al., 1997) ; LMP-1 appears not to induce apoptosis (Table 2) .
LMP-1's inhibition of cell proliferation is reversible and occurs at all phases of the cell cycle Two clones of cells, 293LMP-inducible 1 and 2, which conditionally express LMP-1 under the control of bestradiol, were used to characterize LMP-1's inhibition of proliferation under conditions in which all the cells in a population are genetically equivalent and likely therefore to express the protein similarly. Quantitative Western blots revealed that the expression of LMP-1 was increased at least 10 ± 18-fold over background at 48 ± 144 h, after the addition of b-estradiol (Figure 2a ) (which is 2 ± 4-fold higher levels of LMP-1 expression than in 721 cells, a clone of EBV-immortalized lymphoblasts [data not shown]). These cells neither proliferate nor die over the 168 h of the experiment in the presence of b-estradiol (Figure 2b ). The parental Jurkat cells were transfected via electroporation with 9 mg of plasmid listed in the ®rst column and 1 mg of CMV luciferase. 24 h after transfection the cells were split into two 10 cm dishes and half were treated with 200 ng/ml of aFAS antibody. 24 h after the addition of the aFAS antibody the treated and untreated cells were assayed for luciferase activity. The relative light units for each of the untreated controls was set at 100%. The data represent one experiment with 3 points for each data set The induced cells were assayed at increments of 48 h over 6 days for their DNA content and found to be distributed throughout the cell cycle ( Figure 2d ). More LMP-1-positive cells were in the G2/M phase of the cell cycle throughout the course of the experiment than was found with cycling cells; however, the proportion in G2/M did not change appreciably over the time course of the experiment. This ®nding indicates that although LMP-1 may preferentially arrest cells in G2/ M, the inhibition of cell proliferation is not due to an accumulation of cells in G2/M and may re¯ect that the inhibition of cell proliferation can occur throughout the cell cycle.
Mapping the domains of LMP-1 which contribute to its cytostatic effect
Derivatives of LMP-1 that have mutations which abrogate its patching (EELMP-1) (Bloss et al., 1999) reduce its activation of NF-kB and AP-1 (CD55) (Mitchell and Sugden, 1995; Kieser et al., 1997) , reduce binding of TRAF molecules (Sub 2 and Sub 4) (Sandberg et al., 1997) , remove the entire carboxyterminus (6MHALMP-1EE), or lack its ®rst two transmembrane domains (4MHALMP-1) ( Figure 1 ) were analysed. The levels of expression of LMP-1 and its derivatives were measured in GG68 cells and found to be within threefold of wild-type LMP-1 48 h after vectors expressing them were introduced into the cells (Figure 3a) . The cytostatic eects of LMP-1 and its derivatives were scored in endpoint-dilution assays 3 weeks after their corresponding expression vectors were introduced into GG68 cells and the cells selected in hygromycin B. This assay has been used previously to measure a failure to yield progeny (Hammerschmidt et al., 1989; Martin and Sugden, 1991b) , has a thousandfold signal-to-noise ratio, and allows detection of small functional dierences between the derivatives tested. ND25 and 4MHALMP-1 yield about one-half as many progeny as does the empty vector (Figure 3b ). Those derivatives that are cytostatic yield reduced numbers of cells capable of proliferating in the presence of hygromycin B. The derivatives, 6MHALMP-1, Sub 2, Sub 4, CD55, EELMP-1, and 6MHALMP-1EE behave similarly to wild-type LMP-1 and yield 0.1 ± 2.7% as many progeny as does the empty vector (Figure 3b) . To con®rm the endpoint dilution assay at physiological levels of expression of LMP-1, eight inducible cell lines were generated and analysed. These cell lines conditionally expressed 4MHALMP-1, 6MHALMP-1, 6MHALMP-1EE, or luciferase as a negative control. Quanti®cation of the level of protein expressed in these cells when induced with the addition of tetracycline indicated that the levels of LMP-1 or its derivatives expressed were between one and four times the level of LMP-1 expressed in 721 cells (Figure 3c ). Growth curves of these cells over 6 days in the presence or absence of tetracycline con®rmed the endpoint dilution assays (Figure 3d ). The most intriguing result from these measurements is that 6MHALMP-1EE, which has the entire carboxy-terminus removed and replaced with 2 EE-epitopes, is as cytostatic as is wild-type LMP-1 when expressed at or near physiological levels. Taken together these observations indicate that the amino-terminus and the transmembrane-spanning domains of LMP-1 alone can inhibit cell proliferation.
LMP-1's inhibition of proliferation can protect cells from apoptosis
TNF-R1 not only activates transcription but also induces apoptosis upon binding ligand. It is possible that LMP-1's limiting its own proliferative signaling in fact avoids induction of cellular apoptotic pathways. To test this possibility we determined if the aminoterminus and membrane-spanning domains of LMP-1 could inhibit TNFa-mediated apoptosis (Figure 4 ). In agreement with this model, cells transfected with the amino-terminus and membrane-spanning domains of LMP-1 are more resistant to the eects of TNFa than are cells transfected with vector alone. This observation is consistent with the notion that the amino-terminus and membrane-spanning domains, by inducing cytostasis, may protect cells from external signals that are cytotoxic.
Discussion
The LMP-1 oncoprotein of EBV appears to act as a viral mimic of CD40, a cellular regulator of B-cell proliferation. CD40 positively aects proliferation only in the presence of its ligand, while LMP-1 acts constitutively to maintain proliferation. This contrast raises the question,`What limits LMP-1's signaling?' Ecient expression of LMP-1 dampens cellular proliferation. This constraint does not induce apoptosis in Hep2 cells were transfected via calcium phosphate with 20 mg of the plasmids indicated. 16 h after transfection the cells were trypsinized, disaggregated, and 1000 cells were plated in 6 well plates on 18618 mm glass cover slips. The cells were allowed to proliferate for 72 h at which time all of the colonies on the glass cover slips were counted and scored for the number of cells in the colonies and their EGFP status by using both phase contrast and¯uorescence microscopy. For each derivative the values represent the average of two coverslips for three independent experiments. The dierence in the number of cells per EGFP-colony vs ND25/EGFP-colony is not signi®cantly dierent (P50.05). However, the dierence in the number of cells per EGFP-colony and ND25/EGFP-colony vs LMP/EGFP is signi®cantly dierent (P40.05). All statistical analyses were calculated by Wilcoxon rank sum test LMP-1 inhibit cell proliferation A Kaykas and B Sugden four tested cell lines, in that it is independent of p53 and not inhibited by CrmA, p35, or Bcl-2, proteins known to prevent apoptosis induced through various pathways. Rather, ecient expression of LMP-1 inhibits cellular proliferation by inducing cytostasis throughout the cell cycle. This inhibition is a result of cytostasis and not lysis: cells individually transfected with vectors expressing LMP-1/EGFP fusions yielded the same number of EGFP-positive colonies, as did cells transfected with vectors expressing a mutant of LMP-1 (ND25) fused to EGFP or EGFP alone but contained only an average of 1.4 cells after 72 h (Table   5 ). The average number of cells per colony carrying the ND25/EGFP mutant or EGFP contained 5.5 and 7.1 cells, while non-transfected colonies contained 11 cells after 72 h. These data indicate that ecient expression of LMP-1 stops cells from proliferating but does not induce their death.
One concern with the experiments using LMP-1/ EGFP fusions is that the vectors for these proteins used the cytomegalovirus immediate early promoter, which in transfection experiments can yield levels of LMP-1 70-fold greater than found in EBV-positive Bcells. A series of experiments in which LMP-1 was expressed from either of two inducible promoters at levels one-to four-times that expressed in EBV-positive B-cells induced cytostasis in 293 cells (Figures 2 and 3 ) for at least 6 days. From these data it seems likely that the level of LMP-1 induced in these cells is consistent with LMP-1's induction of cytostasis occurring under physiological conditions to control cell proliferation of EBV-positive cells. Floettmann et al. (1996) have demonstrated that LMP-1 induces cytostasis in cells but some of these cells resume proliferation after 4 days. The renewed proliferation in these experiments may re¯ect those cells which express lower levels of LMP-1 and overgrow the cytostatic cells. In our experiments 3% of the cells yielded proliferating colonies after 21 days (data not shown). Both of these observations can be explained by a selective, proliferative advantage of those cells which express lower levels of LMP-1.
Mapping the domains of LMP-1 required for its induction of cytostasis revealed that the domain of LMP-1 that diers conspicuously from those of CD40, and TNF-R1 encodes this activity. CD40 and TNF-R1 have one membrane spanning region; LMP-1 has a cytoplasmic amino-terminus and six transmembranespanning domains. LMP-1's membrane-spanning segments are crucial for its induction of cytostasis. A derivative of LMP-1, 6MHALMP-1EE, which lacks all of its cytoplasmic carboxy-terminus, is wild-type in its induction of cytostasis. Derivatives of LMP-1 which have an HA epitope between residues two and three of the amino-terminus or substitute an EE epitope for residues 12 through 20, also induce cytostasis, making it likely for these phenotypes that the amino terminus of LMP-1 serves primarily to anchor its ®rst membrane-spanning segment in the membrane. One derivative, 4MHALMP-1, which lacks LMP-1's ®rst two membrane-spanning segments but has its aminoand carboxy-termini correctly oriented in the cytoplasm (Bloss et al., 1999) , is as reduced in the induction of cytostasis when expressed similarly as is ND25 which lacks the amino-terminus needed to anchor its ®rst membrane-spanning segment in the membrane. These observations make it likely that it is the membranespanning segments of LMP-1 which, when correctly oriented in the membrane, act as a governor on cellular proliferation.
The region of LMP-1 that mediates cytostasis contains its transmembrane spanning domains. We propose that the membrane-spanning domains of LMP-1 associate with cellular membrane proteins to induce cytostasis similar to BPV-1 E5's association with the platelet-derived growth factor receptor (Petti and DiMaio, 1994; Petti et al., 1997) . Recently it has been demonstrated that the transmembrane-spanning domain's of LMP-1 activate CDC42 (Puls et al., 1999) . CDC42 is a tantalizing candidate to mediate LMP-1's cytostatic eect. Signaling molecules downstream of CDC42 such as PAK and its family members have been show to inhibit cell proliferation in yeast and frogs (Faure et al., 1997; Rooney et al., 1996) .
There are interesting possible consequences of this formerly unsuspected activity of the amino-terminus and transmembrane spanning domain of LMP-1. First, EBV DNA is gradually ampli®ed after infection of primary B-cells (Sugden et al., 1979) . This ampli®ca-tion probably represents a selection for sucient copies to insure optimal viral expression. However, the number of viral DNAs per cell eventually stabilizes in d Figure 2 LMP-1's inhibition of cell proliferation is reversible and occurs at all stages of the cell cycle. (a) Assay to measure the induction of LMP-1-protein in the 293LMP-inducible cell lines. Quantitative Western blots were performed, as described in Materials and methods, to measure the levels of LMP-1 induced over a 144 h time-course for 293LMP-inducible 1 and 2. First a standard curve was set up by quantifying the amount of LMP-1 induced by comparing the levels of LMP-1 in cells that were untreated or treated with 10 77 M b-estradiol at 48 h by analysing 10 ml (10 5 cell equivalents), 3 ml (3.0610 4 cell equivalents), and 1 ml (1.0610 4 cell equivalents) of the lysates. Quanti®cation of the LMP-1-bands indicate that 293LMP-inducible 1 and 2 had a 18-fold and tenfold induction of LMP-1 respectively at 48 h after the addition of 10 77 M b-estradiol. Next 3 ml cell lysates from cells that were induced with 10 77 M b-estradiol were examined. Quanti®cation of the LMP-1-bands indicated that the levels of LMP-1-expression stay constant (within twofold) for at least 144 h after the addition of 10 77 M b-estradiol. clones that proliferate eciently. This stabilization could be mediated by LMP-1's inhibition of cell proliferation: some level of expression of LMP-1 is optimal for proliferation; more resulting from an increased number of DNA templates would be detrimental to cell proliferation. Second, the expression of LMP-1 is lost during progression of Burkitt's lymphomas which are known to be among the fastest proliferating human tumors (Rowe et al., 1987) . The loss of LMP-1s constraint on proliferation may contribute to the rapid proliferation of these tumors. Third, the mechanism by which LMP-1 limits proliferation also may limit susceptibility of EBV infected cells to external apoptotic signals (Figure 4 ).
Materials and methods
Cell culture
Hep2 is a human epithelial cell line and was obtained from American type culture collection (ATCC CCL 23). (10) Miller, 1983) . GG68 cells lack EBNA2 and express low levels of LMP-1. Jurkat is a clone derived from a human T-cell leukemia and was obtained from ATCC (CRL-8129). GG68 and Jurkat were grown in RPMI 1640 supplemented with 10% fetal bovine serum, 200 U per ml penicillin, and 200 mg per ml streptomycin. 721 is an EBV-positive lymphoblastoid cell line (Kavathas et al., 1980) which expresses EBV's latent genes including LMP-1 and was grown in RPMI 1640 supplemented with 10% fetal calf serum, 200 U per ml penicillin, and 200 mg per ml streptomycin. All cells are grown at 378C in a humidi®ed 5% CO 2 atmosphere.
Generation of inducible cell lines
The 293 cell lines that express LMP-1 under the control of bestradiol were generated by transfecting 293 cells via calcium phosphate precipitation (Graham et al., 1977) with a vector (p1559.12) that contains LMP-1 under the control of LMP2A's promoter and GAL4 binding sites. This vector also expresses a fusion of the GAL4-DNA binding domain, the estrogen receptor ligand-binding domain, and the d Figure 3 Mapping the domains of LMP-1 sucient to inhibit proliferation. (a) Quantitative Western blots were performed to assay expression of LMP-1 and its derivatives. 1.0610 7 GG68 cells were transfected via electroporation with 20 mg of vector or plasmids encoding LMP-1 or its derivatives. Forty-eight hours after transfection the cells were harvested and their lysates were separated electrophoretically on a SDS ± PAGE gel. The samples were then probed with either an aLMP-1 or an aHA antibody and a 35 S-labeled secondary antibody. Finally the Western blots were quanti®ed by phosphorimage analysis. All LMP-1 derivatives were expressed within threefold of wild-type LMP-1. (b) Long-term assay for the inhibition of proliferation to measure the cytostatic eects of LMP-1 and its derivatives on cells. Endpoint-dilutions were performed to measure the number of proliferating cells surviving selection with hygromycin B. 1.0610 7 GG68 cells were electroporated with 20 mg of the plasmid listed in the ®rst column. All plasmids in addition to LMP-1 or its derivatives contain the gene for hygromycin phosphotransferase and oriP and replicate as plasmids in the EBNA-1-expressing cell line GG68. Twenty-four hours after transfection the cells were tested for the expression of the LMP-1 and its derivatives and were serially diluted to 1. 2 cells per well. After 3 weeks of selection with 400 mg per ml hygromycin B the dilutions were scored as positive for growth if 41000 viable cells were present (one surviving cell doubling every 48 h would yield 41000 cells by 3 weeks). The endpoints were determined for each derivative and the number of cells which received vector alone and survived were set at 100%. The survival of cells receiving test plasmids relative to those that received vector alone (+standard deviation) is shown in the middle column. Cells electroporated with the vector alone gave rise to approximately 1 colony/ 1.0610 3 cells plated. (c) Quantitative Western blots were performed to assay expression of LMP-1 and its derivatives in cell lines that conditionally express LMP-1 under the control of tetracycline. 10, 5 and 2.5 ng of a GSTHALMP-1 fusion protein, 5.0610 5 cell equivalents of 721 cells, and of 293 cells induced or uninduced with tetracycline for 48 h for the expression of luciferase, 4MHALMP-1, 6MHALMP-1, and 6MHALMP-1EE were electrophoretically separated on an SDS ± PAGE gel. The samples were then probed with either an aLMP-1 or an aHA antibody and a 35 S-labeled secondary antibody. Finally the Western blots were quanti®ed by phosphorimage analysis and the number of molecules per cell was calculated form the known amounts of GSTHALMP-1. The fold induction of luciferase in the presence of tetracycline was measure on a monolight 3010 luminometer and determined to be between 200-and 500-fold. Cell lines that express derivatives of LMP-1 or luciferase under the control of tetracycline were generated by ®rst transfecting 293EBNA-1 cells via calcium phosphate precipitation with a plasmid that encodes the tetracycline repressor fused to KRAB (Deuschle et al., 1995) and hygromycin phosphotransferase and selecting for cells resistant to 200 mg per ml of hygromycin B. A clone of cells expressing this vector was transfected with vectors encoding luciferase, 4MHALMP-1, 6MHALMP-1, or 6MHALMP-1EE under the control of LMP2A's promoter containing 7 tet operator sites. The vectors also encode puromycin acetyltransferase, EGFP, and OriP. The transfected cells were selected with 1.0 mg per ml of puromycin and two clones of each transfected cell population which exhibited ecient induction with 1.0 mg per ml of tetracycline were chosen for analysis.
Recombinant DNA constructions
The pCMV (vector) (Hammerschmidt et al., 1989 ) is a derivative of pHEBo (Sugden et al., 1985) and contains the latent origin of replication for EBV (oriP), the gene for hygromycin phosphotransferase as a selectable marker in mammalian cells, the ColE1 origin and the b-lactamase gene for propagation and selection in E. coli. pCMV was further modi®ed by placing a BssHII linker down-stream of the CMV immediate early promoter to facilitate cloning (p1348). The ND25 (p1259) and CD55 (p907) derivatives of LMP-1 have been previously described (Hammerschmidt, et al., 1989; Martin and Sugden, 1991b; Mitchell and Sugden, 1995) . Expression vectors for all of the following LMP-1 derivatives were constructed by sub-cloning LMP-1 or its derivatives into pCMV: EELMP-1 (p1463) has an EE epitope (EYMPME) (Wilson and Bourne, 1995) cloned in place of amino acids 12 to 20 of wild-type LMP-1; 6MHALMP-1 (p1652) has the¯u haemagglutinin, HA epitope (YPYDVPDYA) (Arden et al., 1995) between amino acids 2 and 3 of wild-type LMP-1; 4MHALMP-1 (p1653) has a deletion between amino acids 25 to 65 in 6MHALMP-1; 6MHALMP-1EE (p2055) was constructed by cloning an oligonucleotide that encodes that contains the sequence (ILIWMYYHGQHSDEY MPME-VEYMPMEV*) between the BsaB1 and B1p1 sites in the LMP-1 coding sequence of 6MHALMP-1; 4MHALMP2EE was constructed by moving the membrane-spanning domains and the EE-tagged carboxy-terminus of the 6MHALMP-1EE derivative from BstZ17I to BamHI into the 4MHALMP-1 derivative which creates a derivative of LMP-1 that has an HA-tagged amino-terminus fused with last four membranespanning domains of LMP-1 and 2EE epitopes; the Sub2 (p1662) and Sub4 (p1701) mutation have previously been described (Sandberg et al., 1997) and contain substitutions of the histidines and charged amino acid with alanines from residues 205 to 215 and residues 221 to 231 respectively in the wild-type LMP-1 sequence. The fusions between LMP-1 and green¯uorescent protein, LMP/EGFP (p1772) and ND25/ EGFP (p1776) were constructed by fusing the enhanced green uorescent protein from EGFP-N1 (p1704) (Clontech) into LMP-1 or ND25 at the unique MfeI site in the LMP-1 coding sequence which fuses the N-terminus of EGFP to amino acid 323 of LMP-1. pEQ179 (p1258), the b-galactosidase expression vector (Schleiss et al., 1991) used in the short-term assay for the inhibition of proliferation was kindly provided by Adam Geballe. The luciferase expression-vector used to determine whether the CrmA, P35 and Bcl-2 expression vectors inhibit apoptosis contains the luciferase open reading frame driven by the CMV immediate early promoter (p1065).
The vector used to express GSTHALMP-1 in bacteria was generated by fusing an the DNA encoding an HA tagged version of LMP-1's carboxy-terminus (amino acids 189-386) in frame with GST (p2340) in pGEX-4T (pharmacia). The vector used to generate the 293-LMP-1 clones inducible with b-estradiol was constructed by placing GAL4-sites upstream of EBV's LMP-2A promoter driving LMP-1. The vector also expresses a fusion consisting of the GAL4 DNA binding domain, the estrogen receptor ligand-binding domain, and the transactivation domain of VP16 driven by the SV40 early promoter (p1559.12) (kindly provided by Wolfgang Hammerschmidt). It also contains the gene for hygromycin phosphotransferase for selection in mammalian cells. The tetracycline repressor-vector used to generate the 293-LMP-1 clones inducible with tetracycline contains a fusion of the tetracycline repressor and KRAB under the control of the CMV I.E. promoter and encodes the gene for hygromycin phosphortransferase (p2322). The vectors used to express LMP-1 from a tetracycline inducible promoter contain luciferase (p2353), 4MHALMP-1 (p2362), 6MHALMP-1 (p2361), or 6MHALMP-1EE (p2360) under the control of LMP2A's promoter, 7 tetracycline operator site and OriP and contain the genes for EGFP and puromycin acetyltransferase. The vectors encoding inhibitors of apoptosis used in the short-term assay for inhibition of proliferation are as follows: the Bcl-2 expression vector (pSVBcl-2) (Hockenbery et al., 1990) ; the CrmA expression vector (pCrmA) (Tewari et al., 1995) ; the P35 expression vector was constructed by inserting the P35 open reading frame (Bertin et al., 1996) , kindly provided by Paul Friesen, into the pCMV vector (p1583).
Assay for apoptosis
Cells were transfected via calcium phosphate precipitation with 1 mg of EGFP-N1, 10 mg of the plasmids indicated in text and adjusted to a total of 20 mg with pCMV. 24 h post transfection the cells were split onto two plates and half were Figure 4 The amino-terminus and transmembrane domains of LMP-1 inhibit TNFa-mediated apoptosis. Hep2 cells were contransfected with 19 mg of the plasmids indicated and 1 mg of EGFP-N1. Twenty-four hours after transfection the cells were either left untreated or treated with 10 ng/ml of TNFa. Eighteen hours after the addition of TNFa the cells were assayed for apoptosis by scoring 100 EGFP-positive cells for apoptotic morphology as indicated in Materials and methods. The data represent three independent experiments with two points each treated with 10 ng/ml of TNFa (Boerhringer Mannheim). Medium and transfected cells were collected on ice, washed once with PBS, and centrifuged at 2000 r.p.m. The cells were ®xed with 1 ml 1.25% glutaraldehyde in PBS for 5 min, washed once in PBS and stained for 10 min at room temperature with 1 ml of PBS containing 20 ng/ml 4',6'-diamidino-2-phenylindole (DAPI). The cells were washed twice with PBS, resuspended in 50 ml of PBS and 10 ml was allowed to dry onto slides. Cells were examined bȳ uorescence microscopy using a standard FITC ®lter set on a Zeiss Axiophot microscope for both EGFP and DAPI. 100 random EGFP-positive cells were scored per experiment.
Short-term assay for inhibition of proliferation (10)1, (10)3, and Hep2 cells were transfected via calcium phosphate with the vectors and concentrations of DNA as indicated and 2 mg of pEQ176. The total amount of DNA was adjusted to 20 mg of DNA per 10 cm dish of cells with pCDNA-3. 12 ± 16 h after transfection the cells were plated at 2.0610 4 cells per gridded 60 mm tissue culture dish. 48 ± 72 h after plating, the cells were ®xed with 0.7% gluteraldehyde, 10 mM sodium phosphate (pH 7.0) and 1 mM magnesium chloride for 15 min at 258C and washed once with PBS. The cells were than stained with 0.2% X-gal (5-Bromo-4-chloro-3-indolyl-b-D galactopyranoside), 10 mM sodium phosphate (pH 7.0), 150 mM sodium chloride, 3.3 mM potassium ferrocyanide, and 3.3 mM potassium ferricyanide for 2 h. A minimum of 500 cells per plate were scored for the expression of b-galactosidase (b-gal). To test if the expression vectors for CrmA, P35 and Bcl-2 inhibit apoptosis, GG68 cells, which express FAS, were electroporated with vectors for CrmA, P35, or Bcl-2 and a vector for luciferase or a vector for luciferase alone. Twenty-four hours after electroporation the cells were either left untreated or treated with 200 ng per ml of aFAS antibody (CH-11) (Alderson et al., 1994) for 24 h. The cells were then lysed and assayed for luciferase activity with an ALL Monolight 2010 luminometer as described (Mitchell and Sugden, 1995) .
Long-term assay for inhibition of proliferation
Endpoint-dilutions were performed as previously described (Hammerschmidt et al., 1989; Martin and Sugden, 1991b) . 1.0610 7 GG68 cells were electroporated in DMEM supplemented with 10% FBS and 0.05 M HEPES (pH 7.4) with 20 mg of the plasmids indicated. All electroporations were carried out as described (Knutson and Yee, 1987) . The cells were allowed to recover for 24 h at which time they were plated at 1. 
Colony formation assay
Hep2 cells were plated at 5.0610 5 cells per 10 cm dish. Twenty-four hours after plating the cells were transfected via calcium phosphate with the amount of plasmid indicated.
Sixteen hours after transfection the cells were washed once with PBS and removed from the plate with trypsin. The cells were disaggregated using a Pasteur pipette and diluted to 500 cells per ml in DMEM containing 10% calf serum. 2 mls of the cells were then plated on 18618 mm cover slips in six well plates. The cells were allowed to proliferate for 48 ± 72 h at which time they were washed once with PBS and counted on a Zeiss Axiophot microscope using both phase contrast and¯uorescence microscopy with a standard FITC ®lter set.
SDS ± PAGE and Western analysis
The GSTHALMP-1 fusion protein used to quantify the number of molecules of LMP-1 expressed per cells was puri®ed from DH5a as described by Sandberg et al. (1997) . LMP-1, its derivatives, and GSTHALMP-1 were resolved by electrophoresis through a 10% polyacrylamide gel. Proteins resolved by SDS ± PAGE were transferred to nitrocellulose and blocked with Blotto (1% non-fat dry milk and 0.05% Tween-20 in PBS) for 1 h. Blots were probed with anitypuri®ed polyclonal aLMP-1 antibody that recognizes epitopes in the carboxy-terminus of LMP-1 at a 1 : 100 dilution for 1 h at room temperature or a mouse monoclonal aHA antibody (Babco) that recognizes the sequence (YPYDVPDYA) at a 1 : 100 dilution and a a-mouse rabbit IgG (ICN) at 1 : 1000 both for 1 h at room temperature. After washing 10 min with Blotto the blots were probed with 35 S-labeled donkey a-rabbit IgG (Amersham) at a 1 : 1000 dilution (0.5 mCi per blot). The blots were washed twice with Blotto for 10 min at room temperature and exposed to a phosphorimager screen (Molecular Dynamics). The protein was quanti®ed using Imagequant software (Molecular Dynamics).
Cell cycle analysis
Hep2 cells were harvested 48 h after transfection and permeabilized with 0.1% saponin in PBS (Jacob et al., 1991) . The cells were diluted to 1.0610 6 cell per ml in PBS containing 1% calf serum and stained for 1 h with a 1 : 40 dilution of aLMP-1 antibody. The cells were washed twice with PBS containing 1% calf serum and stained for 1 h with a 1 : 100 dilution of FITC-conjugated a-rabbit IgG (ICN). The cells were washed twice in PBS and incubated for 30 min at 1.0610 6 cell per ml in PBS containing 25 mg per ml propidium iodide and 250 mg per ml Rnase A. The 293LMP-inducible cells were harvested at the given time points, ®xed with 70% ethanol at 7208C, and incubated for 30 min at 378C in PBS containing 25 mg per ml propidium iodide and 250 mg per ml Rnase A (Camplejohn, 1994) . Flow cytometry was performed on a Coulter Epics xL running standard software to analyse PI and FITC scatter. Data was further analysed using the multicycle software package (Phoenix software).
